- Poster presentation
- Open Access
Bone health assessment of patients with juvenile idiopathic arthritis: a comparison between DXA and bonexpert
© Nusman et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Bone Mineral Density
- Juvenile Idiopathic Arthritis
- Bone Mineral Density Measurement
- Bone Mineral Density Lumbar Spine
- Juvenile Idiopathic Arthritis Patient
Juvenile idiopathic arthritis (JIA) affects bone mineral density (BMD) due to chronic inflammation, glucocorticoid treatment and immobilization. Dual-energy X-ray absorptiometry (DXA) is most widely used to determine BMD. BoneXpert is a new, feasible and reproducible method for automatic determination of cortical BMD on hand radiographs. Moreover radiation exposure is low and in low-risk peripheral areas.
The aim of this study is to compare BoneXpert and DXA in the assessment of BMD in JIA patients.
Thirty-five JIA patients with available DXA and hand radiograph within the same time period were included from a tertiary hospital of the Dutch Arthritis and Biologicals in Children register. Outcome measures for BMD were Bone Health Index (BHI) from BoneXpert and BMD total body, BMD lumbar spine and Bone Mineral Apparent Density (BMAD) from DXA. For all outcome measures Z-scores were calculated. Correlations between BMD measurements by DXA and BoneXpert were assessed with Pearson correlation coefficients.
The patients in this study had significantly lower mean BMD compared to the healthy population on all BMD measures (p<0.05). The pearson correlation coefficient for the absolute scores of DXA BMD and BHI varied between 0.568-0.770 (p=0.000). The correlation coefficient for the Z-scores of DXA and BoneXpert (0.127-0.322) was not significant.
BHI measured by BoneXpert is correlated to measurements of BMD by DXA. The correlation of Z-scores of BMD measured by the two methods is weaker. Longitudinal studies and assessment of the association of the BMD measurements with outcome (for instance atraumatic fractures) are necessary to determine the value of BoneXpert in clinical use.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.